Ardelyx Inc (ARDX) Stock Price, Quote & News

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 745 1700

Website: www.ardelyx.com

Address:

400 Fifth Avenue, Suite 210, Waltham, United States

Arcides May. 15 at 9:38 PM

piece of shit...$ARDX day trade only stock, has gained nothing since sept...

0 · Reply

gangreen67 May. 15 at 9:19 PM

$ARDX What time is the Zydus Board meeting Monday? Is this a public meeting. I cannot find any link to the meeting on the Zydus site.

1 · Reply

Str8balln May. 15 at 8:36 PM

$ARDX Waiting for my “Monday Merger!”

0 · Reply

FerreroRocher May. 15 at 8:00 PM

$ARDX Is it Monday yet?

0 · Reply

ToadTrader May. 15 at 7:59 PM

$ARDX Just continue to watch this one (ARDX) .... Waiting... As I have no "explanation" I'll simply wish all a Happy and Safe Weekend with hope of a change in "attitude" for ARDX, in coming week! CHEERS!

0 · Reply

bernardbaruch May. 15 at 7:36 PM

$ARDX 13-Fs meh

0 · Reply

MedHS55 May. 15 at 6:15 PM

$ARDX 755 June $9's traded. Assuming just someone collecting premium.

1 · Reply

Berolina May. 15 at 6:04 PM

$ARDX My $5.45 re-entry strategy is progressing to plan. Moved these $ to MSFT and that is going to plan as well. Basically

0 · Reply

Brewersrule May. 15 at 5:24 PM

$ARDX watching level 2 today and market maker MPE is clearly in control of the action. Constantly large shares on bid and or ask

0 · Reply

Burning_Cash May. 15 at 5:19 PM

$ARDX Market’s trash, no positive catalysts anytime soon (I said what I said, for those hoping the courts will save us). We’ll see 5s again IMHO.

0 · Reply

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

2026-04-30T21:07:15.000Z - 15 days ago

Ardelyx reports Q1 EPS (15c), consensus (14c)

Apr 30, 2026, 4:30 PM EDT - 15 days ago

Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:01 PM EDT - 15 days ago

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 27, 2026, 8:01 AM EDT - 18 days ago

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Apr 23, 2026, 8:01 AM EDT - 22 days ago

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

2026-04-22T11:54:28.000Z - 23 days ago

Jade Biosciences appoints Edward Conner as chief medical officer

JBIO

2026-04-20T12:50:41.000Z - 25 days ago

Ardelyx appoints Ettenberg as Chief Legal Officer

Apr 20, 2026, 8:00 AM EDT - 25 days ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

BMY

Apr 16, 2026, 8:01 AM EDT - 4 weeks ago

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

2026-04-01T12:17:42.000Z - 6 weeks ago

Ardelyx appoints Rajani Dinavahi as chief medical officer

Apr 1, 2026, 8:01 AM EDT - 6 weeks ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 10, 2026, 4:20 PM EDT - 2 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:05 PM EDT - 2 months ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

2026-03-05T13:09:46.000Z - 2 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA

Mar 4, 2026, 8:00 AM EST - 2 months ago

Ardelyx to Participate in Upcoming Investor Conferences

2026-02-24T13:18:35.000Z - 2 months ago

Ardelyx, LPGA announce multi-year partnership

Feb 24, 2026, 8:00 AM EST - 2 months ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

2026-02-20T11:12:08.000Z - 3 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-19T22:00:37.000Z - 3 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c

Feb 19, 2026, 4:30 PM EST - 3 months ago

Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:01 PM EST - 3 months ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-19T20:45:39.000Z - 3 months ago

Ardelyx options imply 14.7% move in share price post-earnings

Feb 5, 2026, 8:00 AM EST - 3 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

2026-02-03T13:41:00.000Z - 3 months ago

Ardelyx receives new patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 3 months ago

Ardelyx Receives New Patent for Tenapanor

2026-01-29T14:35:34.000Z - 3 months ago

Ardelyx price target raised to $13 from $10 at TD Cowen

2026-01-28T13:38:18.000Z - 3 months ago

Ardelyx announces first patient dosed in ACCEL

Jan 28, 2026, 8:29 AM EST - 3 months ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

2026-01-27T11:25:47.000Z - 3 months ago

Ardelyx price target raised to $15 from $8 at Jefferies

2026-01-09T12:45:43.000Z - 4 months ago

Ardelyx price target raised to $14 from $11 at Citi

2026-01-09T11:00:13.000Z - 4 months ago

Ardelyx price target raised to $17 from $14 at BTIG

2026-01-08T21:35:56.000Z - 4 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T21:35:25.000Z - 4 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T17:50:15.000Z - 4 months ago

Ardelyx price target raised to $19 from $16 at Raymond James

Jan 8, 2026, 8:30 AM EST - 4 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Nov 19, 2025, 11:30 AM EST - 6 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:30 AM EST - 6 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 7, 2025, 4:05 PM EST - 6 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 5, 2025, 8:00 AM EST - 6 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 6 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Oct 30, 2025, 4:30 PM EDT - 7 months ago

Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:01 PM EDT - 7 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:01 AM EDT - 7 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 13, 2025, 8:35 AM EDT - 7 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:30 AM EDT - 7 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Sep 9, 2025, 11:30 AM EDT - 8 months ago

Ardelyx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Ardelyx Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:35 AM EDT - 9 months ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 9 months ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference

Aug 4, 2025, 4:30 PM EDT - 10 months ago

Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:08 PM EDT - 10 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:01 PM EDT - 10 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 21, 2025, 8:00 AM EDT - 10 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

May 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 6, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 24, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:02 PM EDT - 1 year ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 1 year ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Ardelyx Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 8:02 AM EDT - 1 year ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 9:50 AM EST - 1 year ago

Ardelyx Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings Call Transcript: Q4 2024

Feb 20, 2025, 7:30 AM EST - 1 year ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 8:01 AM EST - 1 year ago

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Arcides May. 15 at 9:38 PM

piece of shit...$ARDX day trade only stock, has gained nothing since sept...

0 · Reply

gangreen67 May. 15 at 9:19 PM

$ARDX What time is the Zydus Board meeting Monday? Is this a public meeting. I cannot find any link to the meeting on the Zydus site.

1 · Reply

Str8balln May. 15 at 8:36 PM

$ARDX Waiting for my “Monday Merger!”

0 · Reply

FerreroRocher May. 15 at 8:00 PM

$ARDX Is it Monday yet?

0 · Reply

ToadTrader May. 15 at 7:59 PM

0 · Reply

bernardbaruch May. 15 at 7:36 PM

$ARDX 13-Fs meh

0 · Reply

MedHS55 May. 15 at 6:15 PM

$ARDX 755 June $9's traded. Assuming just someone collecting premium.

1 · Reply

Berolina May. 15 at 6:04 PM

$ARDX My $5.45 re-entry strategy is progressing to plan. Moved these $ to MSFT and that is going to plan as well. Basically

0 · Reply

Brewersrule May. 15 at 5:24 PM

$ARDX watching level 2 today and market maker MPE is clearly in control of the action. Constantly large shares on bid and or ask

0 · Reply

Burning_Cash May. 15 at 5:19 PM

$ARDX Market’s trash, no positive catalysts anytime soon (I said what I said, for those hoping the courts will save us). We’ll see 5s again IMHO.

0 · Reply

plavac May. 15 at 5:02 PM

$ARDX You keep pushing this theory that the patent expires in 2029, and that has been denied multiple times.

2 · Reply

WinnersParadise May. 15 at 4:49 PM

$ARDX $HKD 5k%

0 · Reply

meadowlarkzac May. 15 at 4:49 PM

$ARDX Opex 🧌

0 · Reply

KevinDL May. 15 at 3:30 PM

$ARDX It appears Janus Henderson lightened their load here by about 6.2 million shares.

4 · Reply

Neutin May. 15 at 2:29 PM

$ARDX That stock is way boring

0 · Reply

KevinDL May. 15 at 2:17 PM

$ARDX no opinions released again today?? Been 2 weeks now since any opinion.

2 · Reply

jstrahan13 May. 15 at 2:12 PM

$ARDX Really, I mean really!

0 · Reply

StellA1918 May. 15 at 12:36 PM

$ARDX script data between now and the end of 2029 is already well known …$1B…knowing that number, the question which must be answered is why is the stock price still only in the $6-$7 range…this, even with every analyst predicting a stock price of $12-$18…something is not right here and it hasn’t been right for the last couple of years and it is not improving…dilution is one reason with the company issuing employee stock options in the amount of 9 million each year moving forward, pushing the share count to 300 million shares

6 · Reply

M_OF_E May. 15 at 11:24 AM

$ARDX Disclaimer- even taking into account stocking and insurance resets I do not believe the script data has been accurate, especially at predicting revenue. So take this with a grain of salt. Ibsrela TRx excellent 4 week change, not at a record but near the highs. Record total patients( 4 week total). NRx not close to getting back to its highs but strongly above average. RRx close to highs. Xphozah TRx up slightly on a 4 week basis. Another new record for Total Patients(4 week total). NRx strong. So while whether TRx is trending up is not quite evident, it is running since sometime in February, well above anything prior to the data change early last year, and the 4 week running total is trending up at this point.

14 · Reply

Cameohitch May. 15 at 9:45 AM

$ARDX Ardelyx and the American Association of Kidney Patients supported this educational Medscape event yesterday: "From Data to the Dialysis Unit: Integrating Novel Therapies for Hyperphosphatemia in Dialysis-Dependent CKD CME/CNE" "Goal statement: The goal of this activity is for learners to be better able to apply key clinical evidence to appropriately integrate novel nonbinder therapies for people with hyperphosphatemia in chronic kidney disease (CKD) who are failing traditional binders." https://events.medscapelive.org/website/94873/

1 · Reply

Ruffy__ May. 15 at 7:13 AM

$ARDX would love to see share price 1 week after q3 numbers.

0 · Reply

opportoni May. 15 at 6:56 AM

$ARDX As long as TDAPA is active for the binders, we are still operating Xphozah in a murky transition phase, despite it already going on for 1.5 years. I expect binder use to collapse when they fall out of TDAPA in 2027, because dialysis care providers will change priorities overnight. With no extra payments for binders the binder pills will become a financial and logistic liability. Xphozah wins, because it is paid for outside the dialysis centers‘ budgets and it has superior efficacy. The only question is whether CMS will find a way to throw a wrench in the works. Those releases a while ago hinted that they are probably willing to do that.

3 · Reply

Market Cap	1.58B
Revenue (ttm)	407.32M
Net Income (ttm)	-61.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.12%
Debt to Equity Ratio	1.37

Volume	3,242,500
Avg Vol	3,716,320
Day's Range	N/A - N/A
Shares Out	247.03M
Stochastic %K	23%
Beta	0.62
Analysts	Strong Sell
Price Target	$16.44